[{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AbobotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor. It inhibits the signaling of IL-23/12 and Type 1 IFN, cytokines involved in the pathogenesis of immune-mediated diseases.

                          Brand Name : Sotyktu

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 27, 2024

                          Lead Product(s) : Deucravacitinib

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.

                          Brand Name : Vtama

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 06, 2023

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : The article focuses on pooled data from 492 Jeuveau®-treated patients who participated in two US multicenter, randomized, double-blind, placebo-controlled, single-dose phase III clinical studies.

                          Brand Name : Jeuveau

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 24, 2021

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : The two Phase II studies, conducted to support the registration and regulatory approval of Jeuveau® in the United States, Canada and Europe, demonstrate that prolonged use of Jeuveau is safe and effective with repeat treatments.

                          Brand Name : Jeuveau

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 12, 2021

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Daewoong Pharmaceutical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : Top-line results showed that 95% of patients treated with Dysport were revealed from severe glabellar lines with two treatments per year, and for 97% the result of the treatment seemed natural.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 12, 2020

                          Lead Product(s) : Botulinum toxin type A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank